← Insider Monitor
MiNK Therapeutics, Inc. logo
INKT

MiNK Therapeutics, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances)

1
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

MiNK Therapeutics develops allogeneic natural killer T (NKT) cell therapies for cancer and other immune-related diseases, derived from its iNKT cell platform licensed from Agenus.

Industry
Biological Products, (No Diagnostic Substances)
Headquarters
New York, NY
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Buell JenniferChief Executive OfficerSell$73KOct 12, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for INKT.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable INKT activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.